This is the authors' abstract. We don't add key points for this paper.
Down syndrome (DS), a genetic condition due to triplication of chromosome 21, is characterized by neurogenesis impairment in the major neurogenic niches of the brain.This defect largely accounts for brain hypotrophy and, hence, intellectual disability in DS.We previously found that treatment with lithium restored the number of proliferating cells in the subventricular zone (SVZ) and of new granule cells in the olfactory bulb (OB) of the Ts65Dn mouse model of DS, suggesting that treatment with lithium may be a potential tool for neurogenesis restoration in DS.The goal of the current study was to establish whether the positive effects of lithium on neurogenesis are retained after treatment cessation.To this aim, adult Ts65Dn mice aged 13 months were treated with lithium for one month, injected with BrdU during the last 3 days of treatment, and killed one month after treatment cessation.We found that in the SVZ of treated Ts65Dn mice there was an increase in the number of cells that were immunopositive for Ki-67, an endogenous marker of cycling cells and an increase in the number of surviving cells (BrdU+ cells).In contrast, the number of BrdU-positive cells in the OB, the terminal destination of neuroblasts from the SVZ, was not increased.These findings indicate that lithium induces long-lasting effects on proliferation and survival of neural progenitors in the SVZ but not in the OB, suggesting that continuous treatment may be needed in order to foster the survival of new granule neurons in the OB.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Renata Bartesaghi (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: